Biotechnology is everywhere: in vaccines that prevent diseases, in drought-resistant crops, in biodegradable bioplastics, and even in the daily detergents we use. But how does a scientific idea transition from the laboratory to a product that impacts the lives of millions?
The report A Primer on Technology Transfer in the Field of Biotechnology by the World Intellectual Property Organization (WIPO) provides a comprehensive guide to understanding this complex and strategic process.
What is Biotechnology?
Biotechnology is the application of science and technology to living organisms or their components to develop useful products and services.
While its roots go back thousands of years (such as fermentation for bread or cheese), modern biotechnology took off in the 20th century with recombinant DNA, genetic engineering and, more recently, tools like CRISPR and genomic sequencing.
Today, it is commonly categorised as:
- Red Biotechnology (Medical): Biological medicines, gene therapies, vaccines, and diagnostics.
- Green Biotechnology (Agricultural): Resistant crops and nutritional enhancement.
- White Biotechnology (Industrial): Enzymes, biofuels, and bioplastics.
From Lab to Market: A Long and Costly Path
The development of a biotechnological product is intensive in terms of time, capital, and regulation. In the case of a medicine, the process can take between 12 and 15 years.
Only a small fraction of the compounds researched actually reach the market. The journey includes:
- Basic research and discovery.
- Pre-clinical studies.
- Clinical trials (Phases I, II, and III).
- Regulatory authorisation application.
- Approval and post-marketing surveillance.
This lengthy process makes the protection of intellectual property (IP) strategic from very early stages.
The Key Role of Patents
Patents in biotechnology do not just protect innovation; they are fundamental for attracting investment. Since products take years to be approved, patents are often applied for very early—frequently before the product is even ready for market. Furthermore, in some countries, mechanisms such as Supplementary Protection Certificates (SPCs) exist to extend patent validity, compensating for long regulatory timelines.
Without a robust IP portfolio, it is extremely difficult to secure the funding required to continue clinical and regulatory development.
Universities and Technology Transfer
A significant portion of biotechnological innovation originates in universities and public research centres. This is where Technology Transfer comes into play: the process by which an academic institution licences its discoveries to companies that can develop and commercialise them.
Technology Transfer Offices (TTOs) manage this process, which may include:
- Exclusive or non-exclusive licences.
- Non-disclosure agreements (NDAs).
- Material transfer agreements (MTAs).
- Public-private collaborations.
- The creation of spin-offs and startups.
Each country has different legal frameworks regulating the ownership and commercialisation of inventions funded by the public purse.
More Than Just Science: Regulation, Funding, and Strategy
Innovation in life sciences does not depend solely on scientific research. It also involves:
- Health and environmental regulations.
- Competition laws.
- Public policies and access to medicines.
- Government incentives.
- International collaborations.
Biotechnology is an ecosystem where science, law, economics, and public health are deeply interconnected.
Innovation with Social Impact
One of the greatest challenges is balancing commercial objectives with humanitarian goals. The COVID-19 pandemic demonstrated the importance of having robust innovation ecosystems and effective collaboration frameworks.
Technology transfer in biotechnology is not just a matter of business: it is a key mechanism for transforming scientific breakthroughs into real-world solutions for society.